Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT06041035
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 300
- Registration Number
- NCT06037980
- Locations
- 🇮🇹
Humanitas Cancer Center, Milan, Italy
🇮🇹Azienda Ospedaliera Universitaria Pisa, Pisa, Italy
🇮🇹ASST Spedali Civili, Brescia, Italy
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT06029270
- Locations
- 🇺🇸
Oncology Associates PC, Omaha, Nebraska, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States
🇺🇸Kaiser Permanente-Fremont, Fremont, California, United States
Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Xuekui Liu
- Target Recruit Count
- 30
- Registration Number
- NCT06023875
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 510
- Registration Number
- NCT06022861
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 57
- Registration Number
- NCT06019130
- Locations
- 🇩🇪
Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany
🇩🇪Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany
🇩🇪Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 28
- Registration Number
- NCT06017297
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peking University Hospital of Stomatology
- Target Recruit Count
- 110
- Registration Number
- NCT06009861
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
🇨🇳Peking University School and Hospital Stomatology, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT06005324
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.